migraine. migraine
Conditions
Interventions
Intervention 1: 1 mL 2% lidocaine plus 0.5 mL 40 mg triamcinolone injected to each Greater Occipital Nerve at the medial third of the distance between the occipital protuberance and the mastoid proces
Treatment - Drugs
Placebo
1 mL 2% lidocaine plus 0.5 mL 40 mg triamcinolone injected to each Greater Occipital Nerve at the medial third of the distance between the occipital protuberance and the mastoid process. Inderal Table
1 mL 2% lidocaine plus 0.5 mL saline injected at the same sites bilaterally. Inderal Tablets are also prescribed as 20 mg twice daily.
Sponsors
Ahvaz Jundishapur University of Medical Sciences Vice of Research And Technology
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Criteria Inclusion Criteria: • Age 18-75 years. • Migraine with or without tenderness. • At least 1 attack per week. • MIDAS score >11 Exclusion Criteria: • Pregnant or lactating. • Continuous headache. • Maintenance opioid medication. • Started migraine prophylactic medication within the past 2 months. • Hypersensitivity to study ingredients. • Injection site infection at injection visit. • Systemic infection at injection visit. • Cranial bone defect. • Chronic cluster headache, new daily persistent headache. • Chronic tension type headache. • Medication overuse headache. • Injection phobia. • Headache due to secondary causes.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Headache severity and frequency. Timepoint: Days 0 - 15 - 30 - 60 of study. Method of measurement: self report of patient. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli Nakhostin Mortazavi
Ahvaz Jundishapour University of Medical Science
Outcome results
None listed